Targeted maintenance therapy with gilteritinib (Xospata; Astellas) following allogeneic hematopoietic stem cell ...
A new Phase 1B/2 trial treated patients with acute myeloid leukemia (AML) in a drug regimen combination of Annamycin and Ara-C. The evaluation of Annamycin in combination with Ara-C (cytarabine) has ...
Menin inhibitors reshape AML care, boosting targeted options for KMT2A- and NPM1-mutant disease, with promising frontline combinations beyond relapsed settings. In an interview with Targeted Oncology, ...
Combining proteasome inhibitors with autophagy inhibitors disrupts acute myeloid leukemia (AML) cells' proteostasis, enhancing treatment efficacy and inducing programmed cell death. The novel therapy ...
SELLAS Life Sciences reports successful Phase 2 trial results for SLS009 in relapsed/refractory AML, exceeding response and survival rates. SELLAS Life Sciences Group has announced that its Phase 2 ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic ...
MedPage Today on MSN
Big jump in therapy-related AML amid growth in population of cancer survivors
Study from Japan shows near-tripling over 30-year period ...
Umbilical cord blood stem cell microtransplantation combined with chemotherapy significantly prolonged disease-free survival (DFS) in patients with acute myeloid leukemia (AML) and high-risk ...
Dr. Gabriel Mannis from Stanford University and Dr. Gail Roboz from Weill Cornell Medicine discussed the evolving treatment landscape for relapsed/refractory NPM1-mutant acute myeloid leukemia (AML) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results